Literature DB >> 8039888

Anticryptococcal resistance in the mouse brain: beneficial effects of local administration of heat-inactivated yeast cells.

E Blasi1, R Mazzolla, R Barluzzi, P Mosci, F Bistoni.   

Abstract

Using a murine model, we have previously shown that brain resistance to local infection with opportunistic fungi is affected by manipulation of the host myelomonocytic compartment. Here, we demonstrate that intracerebral administration of heat-inactivated Cryptococcus neoformans (H-CN) yeast cells results in a consistent enhancement of mouse survival to subsequent local challenge with lethal doses of C. neoformans. The phenomenon, more pronounced upon double H-CN treatment, is associated with (i) massive local inflammatory response, (ii) reduced growth of the fungus within the brain, and (iii) induction of delayed-type hypersensitivity. Moreover, H-CN treatment confers protection against local heterologous challenges. Our data provide initial evidence that intracerebral administration of H-CN results in the establishment of aspecific and specific immune responses; the mechanisms of elicitation and relative contributions to host antimicrobial resistance remains to be elucidated.

Entities:  

Mesh:

Year:  1994        PMID: 8039888      PMCID: PMC302945          DOI: 10.1128/iai.62.8.3189-3196.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  35 in total

1.  Cryptococcal infections in patients with acquired immune deficiency syndrome.

Authors:  R H Eng; E Bishburg; S M Smith; R Kapila
Journal:  Am J Med       Date:  1986-07       Impact factor: 4.965

2.  In vitro reactivity of natural killer (NK) cells against Cryptococcus neoformans.

Authors:  J W Murphy; D O McDaniel
Journal:  J Immunol       Date:  1982-04       Impact factor: 5.422

3.  Cerebrospinal fluid macrophage response to experimental cryptococcal meningitis: relationship between in vivo and in vitro measurements of cytotoxicity.

Authors:  J R Perfect; M M Hobbs; D L Granger; D T Durack
Journal:  Infect Immun       Date:  1988-04       Impact factor: 3.441

Review 4.  Pathology of the mycoses in patients with the acquired immunodeficiency syndrome (AIDS).

Authors:  F W Chandler
Journal:  Curr Top Med Mycol       Date:  1985

5.  Cryptococcosis in the acquired immunodeficiency syndrome.

Authors:  J A Kovacs; A A Kovacs; M Polis; W C Wright; V J Gill; C U Tuazon; E P Gelmann; H C Lane; R Longfield; G Overturf
Journal:  Ann Intern Med       Date:  1985-10       Impact factor: 25.391

6.  Resistance to challenge and macrophage activity in mice previously vaccinated with formalin-killed Cryptococcus neoformans.

Authors:  D M Anderson; M A Dykstra
Journal:  Mycopathologia       Date:  1984-06-30       Impact factor: 2.574

7.  Protective effect of picolinic acid on mice intracerebrally infected with lethal doses of Candida albicans.

Authors:  E Blasi; R Mazzolla; L Pitzurra; R Barluzzi; F Bistoni
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

8.  Correlation of natural killer cell activity and clearance of Cryptococcus neoformans from mice after adoptive transfer of splenic nylon wool-nonadherent cells.

Authors:  M R Hidore; J W Murphy
Journal:  Infect Immun       Date:  1986-02       Impact factor: 3.441

9.  Macrophage-mediated fungistasis in vitro: requirements for intracellular and extracellular cytotoxicity.

Authors:  D L Granger; J R Perfect; D T Durack
Journal:  J Immunol       Date:  1986-01       Impact factor: 5.422

10.  Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment.

Authors:  A Zuger; E Louie; R S Holzman; M S Simberkoff; J J Rahal
Journal:  Ann Intern Med       Date:  1986-02       Impact factor: 25.391

View more
  8 in total

1.  Characterization of IL-22 and antimicrobial peptide production in mice protected against pulmonary Cryptococcus neoformans infection.

Authors:  Karen L Wozniak; Camaron R Hole; Junko Yano; Paul L Fidel; Floyd L Wormley
Journal:  Microbiology (Reading)       Date:  2014-04-23       Impact factor: 2.777

2.  Identification of virulence mutants of the fungal pathogen Cryptococcus neoformans using signature-tagged mutagenesis.

Authors:  R T Nelson; J Hua; B Pryor; J K Lodge
Journal:  Genetics       Date:  2001-03       Impact factor: 4.562

3.  Potent antifungal effects of a new derivative of partricin A in a murine model of cerebral cryptococcosis.

Authors:  T Luna; R Mazzolla; G Romanò; E Blasi
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

4.  Enhanced resistance to Cryptococcus neoformans infection induced by chloroquine in a murine model of meningoencephalitis.

Authors:  R Mazzolla; R Barluzzi; A Brozzetti; J R Boelaert; T Luna; S Saleppico; F Bistoni; E Blasi
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

5.  Biomolecular events involved in anticryptococcal resistance in the brain.

Authors:  E Blasi; R Barluzzi; R Mazzolla; L Pitzurra; M Puliti; S Saleppico; F Bistoni
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

6.  Role of IL-17A on resolution of pulmonary C. neoformans infection.

Authors:  Karen L Wozniak; Sarah E Hardison; Jay K Kolls; Floyd L Wormley
Journal:  PLoS One       Date:  2011-02-17       Impact factor: 3.240

7.  CD44-mediated monocyte transmigration across Cryptococcus neoformans-infected brain microvascular endothelial cells is enhanced by HIV-1 gp41-I90 ectodomain.

Authors:  Xiaolong He; Xiaolu Shi; Santhosh Puthiyakunnon; Like Zhang; Qing Zeng; Yan Li; Swapna Boddu; Jiawen Qiu; Zhihao Lai; Chao Ma; Yulong Xie; Min Long; Lei Du; Sheng-He Huang; Hong Cao
Journal:  J Biomed Sci       Date:  2016-02-20       Impact factor: 8.410

8.  Insights into the mechanisms of protective immunity against Cryptococcus neoformans infection using a mouse model of pulmonary cryptococcosis.

Authors:  Karen L Wozniak; Sailatha Ravi; Sandra Macias; Mattie L Young; Michal A Olszewski; Chad Steele; Floyd L Wormley
Journal:  PLoS One       Date:  2009-09-03       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.